SYNBIOTEC S.R.L. – Trademark Portfolio

Entity Type: 16

SYNBIOTEC S.R.L. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include IMC 501, IMC 502, and IMC 510.

Via Gentile III da Varano 1

I-62032 CAMERINO (MC)

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

IMC 501
IMC 501
Registered 2022
IMC 502
IMC 502
Registered 2022
IMC 510
IMC 510
Registered 2022

Trademark Classifications

SYNBIOTEC S.R.L.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (3 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does SYNBIOTEC S.R.L. have?

SYNBIOTEC S.R.L. has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does SYNBIOTEC S.R.L. file in?

SYNBIOTEC S.R.L. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are SYNBIOTEC S.R.L.'s most well-known trademarks?

SYNBIOTEC S.R.L.'s registered trademark portfolio includes well-known marks such as IMC 501, IMC 502, and IMC 510. These are among 3 currently registered trademarks in the portfolio.

What is SYNBIOTEC S.R.L.'s trademark registration success rate?

SYNBIOTEC S.R.L. has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.